0001493152-23-003456.txt : 20230203 0001493152-23-003456.hdr.sgml : 20230203 20230203060228 ACCESSION NUMBER: 0001493152-23-003456 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230131 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230203 DATE AS OF CHANGE: 20230203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vyant Bio, Inc. CENTRAL INDEX KEY: 0001349929 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 043462475 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35817 FILM NUMBER: 23583610 BUSINESS ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 BUSINESS PHONE: 201.528.9200 MAIL ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS, INC DATE OF NAME CHANGE: 20111216 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS INC DATE OF NAME CHANGE: 20060117 8-K 1 form8-k.htm
0001349929 false 0001349929 2023-01-31 2023-01-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): January 31, 2023

 

VYANT BIO, INC.

(Exact Name of Company as Specified in its Charter)

 

Delaware   001-35817   04-3462475

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

2 Executive Campus

2370 State Route 70, Suite 310

Cherry Hill, NJ 08002

(Address of Principal Executive Offices) (Zip Code)

 

Company’s telephone number, including area code (201) 479-1357

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   VYNT   The Nasdaq Capital Market

 

Indicate by check mark whether the Company is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Introductory Note

 

The Board of Directors (the “Board”) of Vyant Bio, Inc. (the “Company”), after an assessment of the status of the Company’s efforts to seek strategic alternatives and the Company’s current cash position, approved a plan on January 31, 2023 to preserve the Company’s cash to be able to continue to pursue a satisfactory strategic alternative for the purpose of maximizing the value of the Company’s business while also having sufficient cash to adequately fund an orderly wind down of the Company’s operations (the “Cash Preservation Plan”) in the event it is unable to secure a satisfactory strategic alternative.

 

Item 2.05. Costs Associated with Exit or Disposal Activities.

 

As part of the Cash Preservation Plan, the Board determined on January 31, 2023 to conduct a reduction in force as soon as practical, resulting in the retention of a core group of employees required for one or more potential strategic transactions and/or to execute an orderly wind down of the Company if required. The Company estimates that it will incur approximately $1.4 million for retention, severance and other employee termination-related costs in the first and second quarters of 2023. The Company expects to substantially complete the workforce reduction prior to the end of February 2023. The Company also expects to delay or defer pending efforts with respect to its current pre-clinical and clinical programs. As previously reported, LifeSci Capital is engaged as the Company’s financial advisor to assist in exploring a range of strategic alternatives focused on enhancing and maximizing the value of the Company.

 

The estimate of costs that the Company expects to incur and the timing thereof are subject to a number of assumptions, and actual results may differ. The Company may also incur other cash or non-cash charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the decision to wind down our operations.

 

As of January 31, 2023, the Company had cash and cash equivalents of approximately $8.4 million. The estimate is based on currently available information and does not present all necessary information for a complete understanding of our financial condition as of January 31, 2023.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 31, 2023, Vyant Bio, Inc. (the “Company”), John A. Roberts and Robert T. Fremeau, Jr., agreed in principle that Mr. Roberts and Dr. Fremeau would step down as President and Chief Executive Officer and Chief Scientific Officer, respectively, of the Company, effective as of February 3, 2023, and their employment agreements, which are filed as exhibits to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, would be deemed terminated as of that date by the Company without cause for purposes of determining severance thereunder. Such agreement was not the result of any disagreement Mr. Roberts or Dr. Fremeau had with the Company on any matters relating to the Company’s operations, policies or practices. Mr. Roberts will remain a member of the Board of Directors of the Company.

 

Andrew D.C. LaFrence, the Company’s Chief Financial Officer, will assume the role of President and Chief Executive Officer following Mr. Roberts’ departure. Mr. LaFrence became Chief Financial Officer upon the Company’s merger with StemoniX, Inc. on March 30, 2021, pursuant to the terms of an employment agreement, dated March 30, 2021, which will remain in effect. Mr. LaFrence’s biography can be found in the Company’s proxy statement filed with the SEC on June 14, 2022, which is incorporated herein by reference.

 

 

 

 

Item 8.01. Other Events.

 

The description of the Company’s Cash Preservation Plan set forth under the heading “Introductory Note” above and in Item 2.05 is incorporated by reference into this Item 8.01.

 

In addition, as previously disclosed, the Company has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on enhancing and maximizing value including a potential sale or merger of the Company or the licensing of its intellectual property rights. The Company intends to continue to work with LifeSci Capital on identifying and evaluating potential strategic options with the goal of maximizing value, particularly with respect to a sale of its existing business or assets or a reverse merger.

 

There can be no assurance that the activities of LifeSci will result in any changes to the Company’s current business plans or lead to any specific action or transaction. The Company does not intend to discuss or disclose further developments during this process unless and until its Board of Directors has approved a specific action or the Company otherwise determines that further disclosure is appropriate.

 

On February 3, 2023, the Company issued a press release announcing its adoption of the Cash Preservation Plan and the continuing efforts of LifeSci. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press release issued by Vyant Bio, Inc. dated February 3, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

Forward-Looking Statements

 

Any statements in this Form 8-K about future expectations, plans and prospects for the Company, including but not limited to statements about its ability to identify, assess and execute a strategic transaction or realize any value from its existing assets, its ability to preserve cash in order to adequately fund an orderly wind down of the Company’s operations if no transaction is consummated, the ability of creditors, shareholders and other stakeholders to realize any value or recovery as part of a transaction or a wind down process, the ability of the Company to continue as a going concern, the Company’s workforce reduction and future charges expected to be incurred in connection therewith, the adequacy or sufficiency of the Company’s existing cash resources and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to continue to pay its obligations in the ordinary course of business as they come due; the ability to retain key personnel, the adequacy of its capital resources in light of changing circumstances, the actions of creditors of the Company and such other important factors as are set forth in the Company’s annual report on Form 10-K for the year ended December 31, 2021 and quarterly reports and other filings on file thereafter with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this Form 8-K represent the Company’s views as of the date of this Form 8-K. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this Form 8-K.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    VYANT BIO, INC.
       
Date: February 3, 2023 By: /s/ Andrew D. C. LaFrence
    Name: Andrew D. C. LaFrence
    Title: President, Chief Executive Officer and Chief Financial Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Vyant Bio Commences a Cash Preservation Plan Including a Reduction in Force

 

Continuing to Explore Strategic Alternatives

 

CHERRY HILL, N.J., February 3, 2023 — Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that on January 31, 2023 its Board of Directors determined it was appropriate to conduct a reduction in force as soon as practical so as to preserve cash to allow the Company, through its advisors including LifeSci Capital, to continue to pursue satisfactory strategic alternative transactions and/or execute an orderly wind down of the Company, if necessary.

 

John A. Roberts, President and Chief Executive Officer and Robert T. Fremeau, Jr. Ph.D., Chief Scientific Officer agreed in principle with the Company to step down from their respective positions, effective as of February 3, 2023, to preserve cash for the execution of an orderly wind down process. Mr. Roberts will remain a member of the Board of Directors of the Company.

 

The Company’s Board of Directors has appointed Andrew D. C. LaFrence, currently the Company’s Chief Financial Officer, to assume the position of President and Chief Executive Officer to lead the Company through this period of transition.

 

“The Company’s Board and Management believe that it is prudent to allow time for LifeSci Capital to continue its mandate of exploring potential strategic transactions while providing for prudent cash management in the event strategic alternatives fail to materialize and an orderly wind down of the Company’s operations becomes necessary,” said Andy LaFrence, Chief Financial Officer of Vyant Bio.”

 

The Company’s decision to potentially pursue other strategic alternatives to unlock material value is based on its belief that its stock price does not reflect the fundamental value of the business. On January 4, 2023, the Company announced it had engaged LifeSci Capital to assist the Board in evaluating potential strategic options. To arrange a time to meet with the management team, please contact Hany Awadalla at LifeSci Capital at hawadalla@lifescicapital.com.

 

 

 

 

ABOUT VYANT BIO, INC.

 

Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT) is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics for treating the debilitating neurodevelopmental and neurodegenerative disorders for which there are no current therapies. Vyant Bio has built a platform of therapeutics seeking to treat neurodevelopmental and neurodegenerative diseases, with current programs targeting Rett Syndrome (“Rett”), CDKL5 Deficiency Disorders (“CDD”), and familial Parkinson’s Disease. The Company’s approach to drug discovery integrates human-derived biology with artificial intelligence and machine learning technologies to de-risk candidate selection, with the goal of improving the potential effectiveness of drugs discovered earlier in the development cycle. Vyant Bio’s management believes that drug discovery needs to progressively shift to more efficient methods as the widely used models for predicting safe and effective drugs have under-performed, as evidenced by the significant time and cost of bringing novel drugs to patients. By combining sophisticated data science capabilities with highly functional human cell derived disease models, Vyant Bio seeks to leverage its current ability to screen and test therapeutic candidates and create a unique approach to assimilating data that supports decision making iteratively throughout the discovery phase of drug development to identify both novel and repurposed CNS therapeutic candidates.

 

For more information, please visit or follow Vyant Bio at:

 

Internet: www.vyantbio.com

LinkedIn: https://www.linkedin.com/company/vyant-bio

Twitter: @VyantBio

 

Forward Looking Statements:

 

Any statements in this press release about future expectations, plans and prospects for the Company, including but not limited to statements about its ability to identify, assess and execute a strategic transaction or realize any value from its existing assets, its ability to preserve cash in order to adequately fund an orderly wind down of the Company’s operations if no transaction is consummated, the ability of creditors, shareholders and other stakeholders to realize any value or recovery as part of a transaction or a wind down process, the ability of the Company to continue as a going concern, the Company’s workforce reduction and future charges expected to be incurred in connection therewith, the adequacy or sufficiency of the Company’s existing cash resources and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to continue to pay its obligations in the ordinary course of business as they come due; the ability to retain key personnel, the adequacy of its capital resources in light of changing circumstances, the actions of creditors of the Company and such other important factors as are set forth in the Company’s annual report on Form 10-K for the year ended December 31, 2021 and quarterly reports and other filings on file thereafter with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

 

Investor Contact:

 

Vyant Bio, Inc.

Andrew LaFrence, President, Chief Executive Officer and Chief Financial Officer

Email: Andrew.LaFrence@VyantBio.com

 

###

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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vynt-20230131.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 vynt-20230131_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 vynt-20230131_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Jan. 31, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 31, 2023
Entity File Number 001-35817
Entity Registrant Name VYANT BIO, INC.
Entity Central Index Key 0001349929
Entity Tax Identification Number 04-3462475
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2 Executive Campus
Entity Address, Address Line Two 2370 State Route 70
Entity Address, Address Line Three Suite 310
Entity Address, City or Town Cherry Hill
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08002
City Area Code 201
Local Phone Number 479-1357
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol VYNT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001349929 2023-01-31 2023-01-31 iso4217:USD shares iso4217:USD shares 0001349929 false 8-K 2023-01-31 VYANT BIO, INC. DE 001-35817 04-3462475 2 Executive Campus 2370 State Route 70 Suite 310 Cherry Hill NJ 08002 201 479-1357 false false false false Common Stock VYNT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://vyantbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm vynt-20230131.xsd vynt-20230131_lab.xml vynt-20230131_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "vynt-20230131_lab.xml" ] }, "presentationLink": { "local": [ "vynt-20230131_pre.xml" ] }, "schema": { "local": [ "vynt-20230131.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "VYNT", "nsuri": "http://vyantbio.com/20230131", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-01-31to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://vyantbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-01-31to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-003456-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-003456-xbrl.zip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end